GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CEL SCI Corporation
CEL-SCI is a biotech company that has been developing its cancer immunotherapy drug, Multikine, for decades. Its stock price is one of the longest and most speculative stories in biotech, driven by investor confidence in the ultimate success of clinical trials.
Share prices of companies in the market segment - Cancer cure
CEL-SCI Corporation is developing an immunotherapy drug, Multikine, designed to stimulate the immune system to fight head and neck cancer before standard treatment. We've classified it in the "Cancer Cure" segment. The graph below shows the overall dynamics in the immuno-oncology sector, where researchers are seeking ways to "train" the body to attack tumors.
Broad Market Index - GURU.Markets
CEL-SCI is a biotech company developing the immunotherapy drug Multikine for the treatment of head and neck cancer. Its years of research make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how CEL-SCI compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CVM - Daily change in the company's share price CEL SCI Corporation
For CEL-SCI Corporation, a cancer immunotherapy company, daily price change is a measure of extreme volatility. It reflects investor reaction to long-term clinical trials and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
For CEL-SCI Corporation, a cancer immunotherapy company, daily price change is a measure of extreme volatility. It reflects investor reaction to long-term clinical trials and is a critical parameter in risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for decades. The company's stock is steeped in a long scientific struggle, and its price reacts sharply to any news about clinical trials. These dramatic fluctuations, fueled by investor hopes, contribute to the overall market pulse, which is visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CEL SCI Corporation
CEL-SCI Corporation's performance is a multi-year saga surrounding the development of its immunotherapy, Multikine. Its market cap over the next 12 months depends entirely on news of its pivotal clinical trial in head and neck cancer. Its valuation is a bet that, after decades of research, the company will finally be able to prove the effectiveness of its unique approach.
Annual dynamics of market capitalization of the market segment - Cancer cure
CEL-SCI Corporation is a late-stage biotech developing immunotherapy for head and neck cancer. Its stock performance is entirely dependent on the results of its multi-year clinical trial, making it one of the most speculative in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CEL-SCI is one of the longest-running and most speculative stories in biotech. Its stock price has nothing to do with the economy, but rather reflects decades of hope for its drug's approval. Its price is a roller coaster, driven by trial news and the faith of its most staunch investors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CEL SCI Corporation
CEL-SCI is a biotech company that has been developing the Multikine immunotherapy for decades. Its monthly performance reflects the long and highly anticipated history of its key clinical trial. Any news about interactions with the FDA is the main driver of its extreme volatility.
Monthly dynamics of market capitalization of the market segment - Cancer cure
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for head and neck cancer for many years. The company is in late-stage clinical trials, and its future depends entirely on their outcome. The oncology sector's timeline reflects the general interest in immunotherapy, but for CEL-SCI, it all comes down to data from one key study.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CEL-SCI Corporation has been developing immune therapies for cancer treatment for decades. The company's shares are extremely volatile and move solely on news about its lead drug. Their dynamics are completely unrelated to the market and are a classic example of a biotech "hope story" with a binary outcome.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CEL SCI Corporation
CEL-SCI, an old-school biotech company that has been developing cancer immunotherapies for decades, is experiencing extreme volatility. Weekly stock performance hinges on news about its long-term clinical trials, where any development triggers a strong reaction.
Weekly dynamics of market capitalization of the market segment - Cancer cure
CEL-SCI Corporation has been developing Multikine immunotherapy for head and neck cancer for many years. Its shares are extremely volatile and dependent on news. This chart will help separate the hype surrounding its developments from general oncology trends and understand the unique nature of its long investment history.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CEL-SCI is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that CVM dynamics are almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
CVM - Market capitalization of the company CEL SCI Corporation
The CEL-SCI chart is a financial history of the company's multi-year development of immunotherapy for head and neck cancer. Its market cap reflects the faith of dedicated investors in its drug, Multikine. Its extreme volatility reflects the company's long and complex clinical trials, the results of which determine its fate.
CVM - Share of the company's market capitalization CEL SCI Corporation within the market segment - Cancer cure
CEL-SCI's stake in the oncology sector is a multi-year bet on its immunotherapy drug Multikine. Its market share reflects investors' hopes that this unique approach to head and neck cancer treatment will eventually gain approval and change the standard of care.
Market capitalization of the market segment - Cancer cure
CEL-SCI is a biotech company that has been developing an immunotherapy drug for head and neck cancer for decades. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics provide the backdrop to one of the industry's longest and most controversial stories.
Market capitalization of all companies included in a broad market index - GURU.Markets
CEL-SCI is a biotech company that has been developing the immunotherapy drug Multikine for head and neck cancer for many years. Its market capitalization reflects the hope for the success of this long-term project. The chart below shows the economic weight of such persistent R&D companies.
Book value capitalization of the company, segment and market as a whole
CVM - Book value capitalization of the company CEL SCI Corporation
CEL-SCI Corporation's book value is its production capacity for the immunotherapy drug Multikine and its capital. The chart below shows the history of multi-year investments in a single, yet potentially breakthrough, asset.
CVM - Share of the company's book capitalization CEL SCI Corporation within the market segment - Cancer cure
CEL-SCI is a biotech company developing immunotherapies for cancer treatment. It has its own manufacturing facilities. The asset share chart shows how its physical base is an important part of its strategy, providing control over the production of its key drug.
Market segment balance sheet capitalization - Cancer cure
CEL-SCI Corporation is a biotech company. Its main asset is its own manufacturing facility, where its immunotherapeutic drug is produced. This makes it more capital-intensive than purely R&D startups. The graph will show whether this model is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
CEL-SCI's balance sheet is fully focused on the multi-year development of Multikine, an immunotherapy drug for head and neck cancer. The company's assets represent financial resources invested in one of the longest clinical trials in biotechnology history.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CEL SCI Corporation
CEL-SCI is developing an immunotherapy for head and neck cancer. The company has been in development for decades. Its market capitalization reflects the faith of a small group of investors in its drug, Multikine. The chart shows the long and volatile history of hopes associated with this drug.
Market to book capitalization ratio in a market segment - Cancer cure
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for decades. Its value is entirely dependent on the success of its long-suffering drug, Multikine. The chart shows how the market valuation reflects investors' remaining faith in this long-term project.
Market to book capitalization ratio for the market as a whole
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for decades. This chart shows how the market values a company with a long history of development. Its market capitalization reflects the tenacious faith of a small group of investors in the ultimate success of its drug, despite numerous delays and setbacks.
Debts of the company, segment and market as a whole
CVM - Company debts CEL SCI Corporation
CEL-SCI Corporation has been developing immunotherapies for head and neck cancer for decades. Its debt burden reflects the company's extremely lengthy and capital-intensive clinical research journey. This chart shows how the company raises funding to support its decades-long research and development efforts.
Market segment debts - Cancer cure
CEL-SCI Corporation has been developing Multikine immunotherapy for head and neck cancer for many years. Long-term clinical trials require significant and ongoing funding. This chart, showing the general norms for the biotech sector, provides context for the extremely capital-intensive and lengthy journey companies undertake in pursuit of breakthrough treatments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CEL SCI Corporation
CEL-SCI Corporation has been developing an immunotherapy drug for head and neck cancer for decades. It's one of the longest-term projects in biotech history. This chart shows how the company finances its multi-year research. Debt levels are a critical indicator of its ability to continue operations while awaiting regulatory approval.
Market segment debt to market segment book capitalization - Cancer cure
Developing immunostimulant drugs for cancer treatment, like CEL-SCI, is an approach that could complement or replace chemotherapy. This chart shows how the biotech sector funds its R&D. It allows one to assess the financial model of a company that has been developing its lead drug for decades, relative to the broader oncology industry.
Debt to book value of all companies in the market
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for decades. Long-term clinical trials require a constant influx of capital. The chart shows how their long-term debt stacks up against the broader market, which is full of both young and mature companies.
P/E of the company, segment and market as a whole
P/E - CEL SCI Corporation
This valuation for CEL-SCI Corporation, a biopharmaceutical company developing immunotherapy for head and neck cancer, reflects years of investor expectations. The company's value is driven solely by faith in its drug, which is in very late-stage clinical trials.
P/E of the market segment - Cancer cure
This indicator represents the average valuation for the biotech sector covered by CEL-SCI. It reflects the overall level of hope and expectation in the field of cancer immunotherapy. The chart serves as a barometer of investor confidence in the future of drugs that stimulate the immune system to fight disease.
P/E of the market as a whole
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for head and neck cancer for decades. The company's valuation depends entirely on the results of its long and controversial clinical program. This chart of overall market sentiment is irrelevant here. CEL-SCI shares are driven solely by investors' faith or skepticism in a single drug.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CEL SCI Corporation
CEL-SCI Corporation is a biotech company that has spent decades developing its flagship drug, Multikine, a head and neck cancer immunotherapy. Its future depends almost entirely on the drug's approval. This timeline reflects the long-term and highly speculative expectations of investors regarding the final regulatory approval and commercial potential.
%20P%2FE%20CEL%20SCI%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CEL-SCI-Corporation&v=1772654717186 "Chart of the company's future (projected) P/E CEL SCI Corporation")
Future (projected) P/E of the market segment - Cancer cure
CEL-SCI Corporation has been developing Multikine, a drug designed for the immunotherapy of head and neck cancer, for many years. It's a long and complex history with mixed results. This chart reflects expectations for the biotech sector, helping to understand how the market views this company with its very long development cycle.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772654717192 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
CEL-SCI Corporation has been developing Multikine immunotherapy for head and neck cancer for many years. Their approach involves stimulating the immune system before standard treatment. This graph of general expectations reflects investor sentiment toward long-established biotech companies. Market optimism could give the company the opportunity to attract the necessary funding to complete its journey.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772654717215 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for the treatment of head and neck cancer for many years. This timeline reflects the long and arduous journey of biotechnology. The company's future profitability depends entirely on the results of its key clinical trial and subsequent approval of the drug.
Profit of companies in the market segment - Cancer cure
NeuroSense Therapeutics is an Israeli biotech company developing drugs to treat neurodegenerative diseases such as ALS. This graph reflects the state of one of the most complex areas of medicine, where the need for treatment is enormous, but scientific challenges make the path to effective drug development and profitability very long and risky.
Overall market profit
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for many years. The company is in late-stage clinical trials of its drug, Multikine. Its story exemplifies the long and arduous journey of biotech development, where one successful outcome can change everything, regardless of the economic climate.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for the treatment of head and neck cancer for many years. The company's revenue forecast is entirely dependent on the results of its long-term clinical trials and regulatory approval. This chart reflects analysts' highly speculative and long-term expectations.
%20profit%20of%20the%20company%20CEL%20SCI%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CEL-SCI-Corporation&v=1772654717288 "Graph of future (projected) profit of the company CEL SCI Corporation")
Future (predicted) profit of companies in the market segment - Cancer cure
CEL-SCI Corporation has been developing its Multikine immunotherapy for head and neck cancer for decades. It has one of the longest track records in biotech, and the company is approaching breakthrough results. This chart shows profitability projections for the oncology sector. It reflects the enormous risks and patience required to develop breakthrough treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772654717368 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
CEL-SCI Corporation has been developing an immunotherapy drug for head and neck cancer for many years. The company's success depends entirely on the results of its key clinical trial. The overall economic outlook, reflected in this chart, influences investor sentiment and their willingness to continue funding long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772654717388 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for head and neck cancer for many years. The company has no commercial revenue, and its valuation reflects its long and complex clinical trial history and investor expectations for potential approval.
P/S market segment - Cancer cure
CEL-SCI Corporation is a late-stage clinical development biopharmaceutical company developing Multikine® immunotherapy for head and neck cancer. Its future revenue is contingent on the approval of this drug. This chart shows the average valuation in the sector, allowing one to assess the market's perception of CEL-SCI's revenue potential.
P/S of the market as a whole
CEL-SCI Corporation is developing Multikine, an immunotherapy designed to stimulate the immune system to fight head and neck cancer before standard treatment. This chart, showing average valuations, clearly demonstrates the significant premium investors place on the company's revenue potential, offering a fundamentally new approach to oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CEL SCI Corporation
CEL-SCI Corporation is developing the immunotherapy drug Multikine, designed to stimulate the immune system to combat head and neck cancer. This timeline reflects the enormous expectations and risks associated with multi-year clinical trials. The valuation depends entirely on investor confidence in the potential approval and future sales of this drug.
%20P%2FS%20CEL%20SCI%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CEL-SCI-Corporation&v=1772654717442 "The graph of the company's future (projected) P/S CEL SCI Corporation")
Future (projected) P/S of the market segment - Cancer cure
CEL-SCI Corporation is developing Multikine, an immunotherapy designed to stimulate the immune system to fight cancer before standard treatments (surgery, radiation therapy). The chart shows how investors estimate CEL-SCI's future sales, betting on the success of its unique approach to treating head and neck cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772654717461 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
This chart reflects the hopes associated with new approaches to cancer immunotherapy. CEL-SCI is developing Multikine, a drug designed to stimulate the immune system before standard treatment. The potential of their therapy to "wake up" the immune system to more effectively fight tumors supports investor confidence in new treatment paradigms.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772654717514 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for the treatment of head and neck cancer for many years. Being in late-stage clinical trials, the company has not yet generated commercial revenue. This timeline reflects its long and costly research, funded by investors in anticipation of drug approval.
Sales of companies in the market segment - Cancer cure
CEL-SCI Corporation has been developing its drug Multikine for decades, designed to stimulate the immune system to fight head and neck cancer before standard treatment. This chart shows total revenue in the targeted oncology sector. It illustrates the long and arduous journey biotech companies have taken to prove the effectiveness of their innovative approaches.
Overall market sales
CEL-SCI Corporation is a biopharmaceutical company developing Multikine, an immunotherapy designed to stimulate the immune system to fight head and neck cancer before standard treatment. The company is in late-stage clinical trials. Its future depends entirely on the regulatory approval of its drug. Overall economics have little impact.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for the treatment of head and neck cancer for many years. The company's future depends entirely on regulatory approval for this drug. The chart shows highly speculative analyst revenue forecasts, which are a bet on Multikine's long-awaited commercial launch.
%20sales%20of%20the%20company%20CEL%20SCI%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CEL-SCI-Corporation&v=1772654717734 "Schedule of future (projected) sales of the company CEL SCI Corporation")
Future (projected) sales of companies in the market segment - Cancer cure
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for many years. It is designed to stimulate the immune system to fight head and neck cancer before standard treatment. This chart shows projected revenues for the entire oncology sector, providing insight into overall expectations for the immunotherapy market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772654717749 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for many years. The company is in late-stage clinical trials, and its fate depends on regulatory approval. This overall economic performance has little direct impact on the company, whose value is determined solely by the performance of its lead drug.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772654717836 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CEL SCI Corporation
CEL-SCI Corporation has been developing the immunotherapy drug Multikine for the treatment of head and neck cancer for many years. This metric is a financial chronicle of this long journey. It reflects the accumulated investment in research and clinical trials that precede the product's potential commercial launch.
Market segment marginality - Cancer cure
CEL-SCI Corporation is developing an immunotherapy for head and neck cancer. Being in late-stage clinical trials, profitability is a key future metric. This chart reflects its current operational structure and the significant investment in its lead drug compared to other oncology companies.
Market marginality as a whole
CEL-SCI Corporation is a late-stage biopharmaceutical company whose flagship drug, Multikine, is designed for the immunotherapy of head and neck cancer. Their future depends on the results of a long-term study. This overall profitability curve doesn't affect their operations; all attention is focused on clinical trial data.
Employees in the company, segment and market as a whole
Number of employees in the company CEL SCI Corporation
CEL-SCI Corporation has been developing Multikine immunotherapy for head and neck cancer for many years. This track record reflects the company's tenacity and focus. A small but dedicated team of scientists and clinical trial managers is leading one of the longest and largest projects in the history of the biotech industry.
Share of the company's employees CEL SCI Corporation within the market segment - Cancer cure
CEL-SCI Corporation has been developing Multikine immunotherapy for head and neck cancer for decades. This chart shows the concentration of unique scientists dedicated to this project. This share reflects the company's dedication to bringing its flagship and only drug to market.
Number of employees in the market segment - Cancer cure
CEL-SCI Corporation is a biotech company developing Multikine, an immunotherapy designed to stimulate the immune system to fight head and neck cancer before standard treatment. This chart shows overall occupancy in the cancer treatment sector. It illustrates the company's unique approach to "awakening" the immune system before surgery and chemotherapy.
Number of employees in the market as a whole
For several decades, CEL-SCI Corporation has been developing Multikine, an immunotherapy designed to activate a patient's immune system to fight head and neck cancer before standard treatment. This graph illustrates the labor market, where even small but persistent biotech companies can maintain a staff of scientists for decades in pursuit of scientific breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CEL SCI Corporation (CVM)
CEL-SCI Corporation is a biotech company developing immunotherapy for head and neck cancer. This chart is a prime example of a late-stage biotech. The very high market capitalization per employee shows that investors are pricing in the drug's potential success in clinical trials. Value is generated by intellectual property.
%20of%20the%20company%20CEL%20SCI%20Corporation%20(CVM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CEL-SCI-Corporation-CVM&v=1772654718042 "Chart of market capitalization per employee (in thousands of dollars) of the company CEL SCI Corporation (CVM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
CEL-SCI Corporation has been developing immunotherapy for head and neck cancer for many years. Their pricing is entirely dependent on the results of long-term clinical trials. This figure reflects the investors' immense patience and hope. The high price is a bet that their years of effort will finally pay off and lead to a breakthrough in cancer treatment.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772654718209 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
CEL-SCI Corporation is a biopharmaceutical company that has been developing immunotherapy for head and neck cancer for decades. Its valuation reflects a long-term bet on the success of a single drug. The extremely high and volatile valuation per employee reflects the company's tenacity and investors' hopes for a positive outcome from its multi-year research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772654718279 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CEL SCI Corporation (CVM)
CEL-SCI (CVM) is a biotech company that has been developing a single product for decades—the Multikine immunotherapy for head and neck cancer. It's an all-or-nothing R&D business. This chart shows the massive accumulated losses (research expenses) per employee awaiting the FDA's decision.
%20Chart%20CEL%20SCI%20Corporation%20(CVM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CEL-SCI-Corporation-CVM&v=1772654718305 "Company Profit Per Employee (in thousands of dollars) Chart CEL SCI Corporation (CVM)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
CEL-SCI is a biotech company that has been in late-stage cancer immunotherapy development for years. This timeline is a goal they've been striving for for decades. If their drug, Multikine, is ever approved, it could generate high profits, but until then, the company remains R&D-focused with negative margins.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772654718319 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
CEL-SCI (CVM) is a biotech company that has been developing the immunotherapy drug Multikine for head and neck cancer for decades. Their business is focused on single-product R&D. This graph shows the enormous accumulated losses per employee awaiting clinical trial results.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772654718330 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CEL SCI Corporation (CVM)
For CEL-SCI Corporation, a company developing immunotherapy for head and neck cancer, this graph reflects decades of research. Future revenue growth per employee depends solely on the approval and commercial success of its long-developed drug, Multikine.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CEL-SCI-Corporation-CVM&v=1772654718358 "Sales chart per company employee CEL SCI Corporation (CVM)")
Sales per employee in the market segment - Cancer cure
CEL-SCI Corporation is a late-stage biopharmaceutical company developing the Multikine immunotherapy for head and neck cancer. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their R&D team is in advancing their lead drug compared to other oncology biotechs.
Sales per employee for the market as a whole
CEL-SCI (CVM) is a biopharmaceutical company developing an immunotherapy (Multikine) for the treatment of head and neck cancer. The company is in the very late stage, but still in R&D. This metric is critical for CVM: it's at zero. Future growth will signal the drug's long-awaited approval and the start of commercial sales.
Short shares by company, segment and market as a whole
Shares shorted by company CEL SCI Corporation (CVM)
CEL-SCI Corporation has been trying to bring its cancer immunotherapy drug Multikine to market for decades. The company suffered a massive Phase 3 trial failure. This chart shows how many investors are betting that after decades of failure, the company has no chance of success and its drug will never be approved.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CEL-SCI-Corporation-CVM&v=1772654718417 "Short Shares Chart for the Company CEL SCI Corporation (CVM)")
Shares shorted by market segment - Cancer cure
CEL-SCI (CVM) is a biopharmaceutical company that has been developing the Multikine immunotherapy for head and neck cancer for decades. This chart shows the aggregate short position in the oncology biotech sector. It reflects investors' extreme and long-standing skepticism about the company's clinical data and its chances of approval.
Shares shorted by the overall market
CEL-SCI (CVM) is a biotech company that has been in R&D for decades. When this market fear indicator rises, investors run out of patience. They sell off unprofitable "research projects" like CVM en masse, preferring companies with real profitability "here and now."
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CEL SCI Corporation (CVM)
This chart shows a multi-year "miracle bet" on CEL-SCI stock. The company has been developing its drug, Multikine, for head and neck cancer for decades. "Overheating" (above 70) occurs with any positive signal, even weak, from their protracted Phase 3 trial. A failure in this trial or the need to raise more capital keeps the oscillator deeply oversold.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CEL-SCI-Corporation-CVM&v=1772654718457 "RSI 14 indicator chart for the company's stock CEL SCI Corporation (CVM)")
RSI 14 Market Segment - Cancer cure
CEL-SCI (CVM) is a biotech, cancer-hunting stock (with a long history). Their specialty is immunotherapy (Multikine), which trains the immune system before surgery. The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is CVM's growth due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
CEL-SCI (CVM) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CVM (CEL SCI Corporation)
CEL-SCI is a biotech whose fate has been tied for decades to a single drug: Multikine, an immunotherapy for head and neck cancer. This chart shows the highly speculative average price target from analysts, which depends entirely on their belief in the (unlikely) approval of this drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CVM-CEL-SCI-Corporation&v=1772654718520 "A chart showing analyst consensus forecasts for the expected stock price. CVM (CEL SCI Corporation)")
The difference between the consensus estimate and the actual stock price CVM (CEL SCI Corporation)
CEL-SCI (CVM) is a biotech company that has been developing its lead drug, Multikine, for head and neck cancer for decades. This chart is a barometer of their R&D. It measures the gap between the price (low after a failure) and the consensus target, reflecting whether analysts believe (if at all) that they have a "last chance."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CVM-CEL-SCI-Corporation&v=1772654718586 "A chart showing the difference between the consensus forecast and the actual stock price. CVM (CEL SCI Corporation)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
CEL-SCI (CVM) is a biotech company that has been developing the "immunostimulant" Multikine for head and neck cancer for decades. This chart shows the overall expectations of oncology analysts. It reflects whether experts believe this long-awaited R&D project will succeed or whether they consider it hopeless.
Analysts' consensus forecast for the overall market share price
CEL-SCI Corporation is a biotech company that has been developing a drug (Multikine) for immunotherapy of head and neck cancer for decades. It's one of the oldest stories in biotech. This chart shows the overall risk appetite. For CEL-SCI, whose price is an option on (unlikely) FDA approval, overall market optimism (risk appetite) is critical to maintaining investor interest.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CEL SCI Corporation
CEL-SCI is a long-established biotech company that has placed a bet on a one-stop solution with its drug Multikine. It's an immunotherapy designed to awaken the immune system before head and neck cancer surgery. This chart summarizes their R&D journey, reflecting their multi-year clinical trials and their complex dialogue with the FDA.
AKIMA Market Segment Index - Cancer cure
CEL-SCI Corporation (CVM) is a biotech company that has been developing its flagship immunotherapy drug, Multikine, for the treatment of head and neck cancer for decades. The chart shows the segment average. It allows investors to compare CVM's long development history and associated risks with the average level and expectations of the cancer drug development sector.
The AKIM Index for the overall market
CEL-SCI is a biotech company that has been developing Multikine, an immunotherapy for head and neck cancer, for decades. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this controversial and long-running company, awaiting regulatory approval, stacks up against overall economic trends.
